[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yan'an Affiliated Hospital of Kunming Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100629032","clear-as-ct-ffr-guided-revascularization-in-patients-with-severe-aortic-stenosis-100629032",false,"NCT07469371","CLEAR-AS: CT-FFR-Guided Revascularization in Patients With Severe Aortic Stenosis","CT-FFR-Guided Revascularization in Patients With Severe Aortic Stenosis: A Randomized Controlled Trial","CLEAR-AS","Inclusion Criteria:\n\n1. Age \\>18 years.\n2. Severe aortic stenosis confirmed by echocardiography, defined as peak aortic jet velocity (Vmax) ≥4.0 m\u002Fs, mean transvalvular gradient ≥40 mmHg, or aortic valve area (AVA) ≤1.0 cm² \\[or indexed aortic valve area (AVAi) ≤0.6 cm²\u002Fm²\\].\n3. New York Heart Association (NYHA) functional class II or higher.\n4. Eligible for both transfemoral transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR).\n5. Undergoing preoperative coronary computed tomography angiography (CCTA).\n6. Willing to participate in the study and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Allergy to prosthetic valve materials or iodinated contrast agents.\n2. Contraindication or allergic reaction to anticoagulants or antiplatelet agents, or inability to tolerate required anticoagulant or antiplatelet therapy.\n3. Active infective endocarditis or any other active infection.\n4. Severe vascular disease precluding safe implantation of a prosthetic valve.\n5. Ascending aortic diameter ≥50 mm.\n6. Prior prosthetic valve implantation in any cardiac position or prior coronary artery bypass grafting (CABG).\n7. Preoperative imaging confirming aortic root anatomy unsuitable for transcatheter aortic valve implantation.\n8. Intracardiac mass, left ventricular or left atrial thrombus, or vegetation confirmed by preoperative echocardiography.\n9. Acute myocardial infarction within 30 days before surgery.\n10. Clinically diagnosed stroke or transient ischemic attack within 3 months before surgery.\n11. Bleeding or coagulation disorders within 3 months before surgery that required hospitalization or blood transfusion or were otherwise clinically significant and would preclude the antiplatelet therapy required in this study.","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","Severe aortic stenosis (AS) is often accompanied by coronary artery disease (CAD). While coronary computed tomography angiography (CCTA) is routinely used before aortic valve replacement (AVR) to evaluate coronary anatomy, it lacks physiological assessment of myocardial ischemia.\n\nThis prospective, single-center, randomized controlled trial aims to evaluate whether integrating functional assessment using CT-derived fractional flow reserve (CT-FFR) with CCTA can optimize revascularization decision-making and improve clinical outcomes. A total of 300 severe AS patients scheduled for transcatheter or surgical AVR will be randomly assigned to either the experimental group (revascularization decisions guided by both CCTA and CT-FFR) or the control group (decisions guided by CCTA alone). Participants will be followed up for 1 year to assess major adverse cardiovascular events and other clinical outcomes.",[27],"Severe Aortic Stenosis","RECRUITING","2026-04-13",{"date":31,"type":32},"2026-04-16","ACTUAL",{"date":34,"type":32},"2026-04-01",{"date":36,"type":21},"2027-12-01",{"name":38,"class":39},"Yan'an Affiliated Hospital of Kunming Medical University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":40},"100584698","safety-and-efficacy-of-tevar-combined-with-long-bare-metal-stents-in-the-intervention-of-atbad-100584698","NCT06892730","Safety and Efficacy of TEVAR Combined With Long Bare-metal Stents in the Intervention of ATBAD","Safety and Efficacy of TEVAR Combined With Long Bare-metal Stents in the Intervention of ATBAD: a Prospective and Cohort Study","SAFE-COVER","Inclusion Criteria:\n\n* ≧18 years old, ≦80 years old;\n* Acute phase with a course of disease ≦14 days;\n* CTA confirmed diagnosis of active dissection type B in accordance with the Stanford classification in the ESC guidelines, and requiring TEVAR surgery;\n* For patients with acute non-type A and non-type B aortic dissection involving the left subclavian artery: current technologies (such as fenestration, single branch, chimney, etc.) can be used to solve the reconstruction of the left subclavian artery;\n* The distal end of the dissection exceeds the renal artery plane;\n* Signed informed consent (emergency waiver applicable), with primary intervention using CTAG devices. Adjunctive procedures may include LSA revascularization, percutaneous fenestration, aortic\u002Fperipheral stenting, surgical fenestration, or bypass grafting.\n* Medical record completeness \\>90% with mandatory CTA data;\n* Protocol compliance including follow-up adherence\n\nExclusion Criteria:\n\n* Dissection termination above renal arteries;\n* Major aortic surgery within 30 days prior (except LSA revascularization);\n* Iliofemoral stenosis\u002Fangulation precluding endovascular access;\n* Non-diagnostic CTA image quality;\n* Indeterminate symptom onset time;\n* Traumatic TBAD, intramural hematoma, or penetrating aortic ulcer;\n* Complete thoracic aortic thrombosis pre-TEVAR;\n* Re-intervention within 12 months post-TEVAR for non-aortic indications;\n* Renal failure: Baseline serum creatinine \\>2.5 mg\u002FdL (high-risk for contrast nephropathy);\n* Known device material hypersensitivity;\n* Systemic infection increasing endograft infection risk;\n* Evidence of aortic infection;\n* Connective tissue disorders (e.g., Marfan syndrome);\n* Bowel necrosis from visceral ischemia;\n* Participation in other device\u002Fdrug trials within 1 year;\n* Moribund status: ASA class 5 with \\\u003C24h life expectancy;\n* Refractory shock (SBP \\\u003C90 mmHg);\n* Pregnancy or lactation;\n* Active substance abuse.","80 Years",{"count":51,"type":21},200,[24],"The primary objective of this study is to evaluate the safety and efficacy of the TEVAR combined with extended bare-metal stenting (distal landing zone ≥2 cm below renal arteries) in patients with acute complicated type B aortic dissection (ATBAD).\n\nAdditionally, to prevent postoperative true lumen hypoperfusion in residual thoracoabdominal aortic dissection (visceral zone, infrarenal aorta, and iliac arteries) and persistent ischemic manifestations in visceral and lower extremity arteries post-endovascular repair, extended bare-metal stents are deployed to maintain adequate distal true lumen patency. This strategy ensures perfusion to visceral branches and lower limbs while preparing for future complete endovascular aortic repair.",[55],"Aortic Dissection Type B",[57,58,59,60],"ATBAD","TEVAR","Extension","Long bare metal scaffolding devices","NOT_YET_RECRUITING","2025-03-21",{"date":64,"type":32},"2025-03-25",{"date":66,"type":21},"2025-03-31",{"date":68,"type":21},"2027-03-31",{"name":38,"class":39},""]